Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04088929 · ClinicalTrials.gov registry record · Phase 2
The Use of a Water Soluble Under the Tongue (Sublingual) CBD Tablet for Treating Pain Associated With Diabetic Peripheral Neuropathy
A Phase 2 study of Diabetic Neuropathies, sponsored by Pure Green.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT04088929: Completed Phase 2 study of Diabetic Neuropathies, sponsored by Pure Green.
NCT04088929 is a Phase 2 study of Diabetic Neuropathies that has completed, run by Pure Green. The registered enrollment target is 32 participants, below the 324-participant average among 8 other Diabetic Neuropathies trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04088929, a Phase 2 study of Diabetic Neuropathies, has completed, sponsored by Pure Green.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
Use of Cannabidiol for the treatment of Diabetic Neuropathic Pain.
Primary Outcome
To evaluate the safety and efficacy of Pure Green CBD sublingual tablets for the treatment of chronic diabetic neuropathic pain patients by evaluating their daily pain scale score reported as 0-10 where 0 is no pain and 10 is the worst pain possible as self-reported with every dose taken by the patient in the smart phone app. The objective is to reduce the patients average daily pain scale score to less than 5.
Conditions Studied
Interventions
- DRUG CBD
Study Locations (1)
Michigan
- Dr. Nakadar's Office - Sterling Heights
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2019-09-30 |
| Est. Completion | 2019-12-01 |
| Phase | Phase 2 |
What the finished NCT04088929 record still lists
NCT04088929 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 324-participant average among 8 other Diabetic Neuropathies trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Diabetic Neuropathies appearing as the primary indexed condition, and to 1 intervention - of which CBD is the first listed.
NCT04088929 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT04088929 about?
NCT04088929 is a clinical study titled "The Use of a Water Soluble Under the Tongue (Sublingual) CBD Tablet for Treating Pain Associated With Diabetic Peripheral Neuropathy". Use of Cannabidiol for the treatment of Diabetic Neuropathic Pain.
What is the current status of trial NCT04088929?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2019-09-30. Estimated completion is 2019-12-01.
What conditions does trial NCT04088929 study?
This clinical trial studies the following conditions: Diabetic Neuropathies.
What interventions are being tested in trial NCT04088929?
The interventions under investigation include: CBD (DRUG).
Who is sponsoring clinical trial NCT04088929?
This trial is sponsored by Pure Green, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04088929 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Neuropathies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04088929's enrollment target sits among peer trials
32 8th of 8 higher than 1 of 8 other Diabetic Neuropathies trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetic Neuropathies trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy and Safety of TAK-583 in Subjects With Diabetic Peripheral Neuropathy
COMPLETED · Phase 2
-
Cebranopadol Efficacy and Safety in Diabetic Patients Suffering From Chronic Pain Caused by Damage to the Nerves
COMPLETED · Phase 2
-
Omega-3 Fatty Acid Lipidomics in Diabetes Peripheral Neuropathy
RECRUITING · Phase 1
-
Optimization of NIBS for Diabetic Neuropathy Neuropathic Pain
ACTIVE NOT RECRUITING · NA
-
Thermal Screening for Early Diabetic Peripheral Neuropathy (DPN)
COMPLETED
-
Treatment of Peripheral Neuropathy in Patients With Diabetes
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI